By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Sirnaomics 

401 Professional Drive
Suite 280
Gaithersburg  Maryland  20879  U.S.A.
Phone: 301-740-1730 Fax: 301-740-1731


SEARCH JOBS

Sirnaomics is leveraging an unsurpassed level of knowledge and experience in RNA interference (RNAi) technology and forging a path to high value creation with exciting clinical product development programs in multiple therapeutic areas. Sirnaomics, Inc. was established in 2007 by a group of leading scientists from top US pharmaceutical companies.

YEAR FOUNDED:

2007

LEADERSHIP:

Founder and CEO: Patrick Y. Lu

CMO: Michael Molyneaux

COO: Marc M. LemaƮtre


Key Statistics


Email: info-office@sirnaomics.com
Ownership: Private

Web Site: Sirnaomics
Employees:
Symbol: 
 









Company News
Sirnaomics Initiates A Clinical Phase IIa Study Of Its Leading Sirna Therapeutic Candidate, STP705, For Treatment Of Hypertrophic Scar 2/6/2017 8:38:56 AM
Sirnaomics Received Green Light From US FDA For A Clinical Phase IIa Study Of Its Leading Sirna Therapeutic Candidate, STP705, For Treatment Of Hypertrophic Scar 11/8/2016 9:34:16 AM
Sirnaomics Raises $10 Million And Forges A Path To Clinical Development Of Its Anti-Fibrosis Rnai Therapeutics 5/4/2016 6:53:25 AM
Sirnaomics And Partner Submit IND To CFDA For Its First Anti-Fibrosis siRNA Therapeutic 1/5/2015 7:05:40 AM
Sirnaomics Strengthens Its IP Position For Advancing The Company's Novel siRNA Therapeutics Programs 7/8/2014 10:12:41 AM
Sirnaomics Advances Its Novel siRNA Therapeutics Against HPV Infection and Cervical Cancer 12/19/2012 9:51:06 AM
Sirnaomics Received National Institutes of Health (NIH) SBIR Grant for Developing Its Scarless Wound Healing siRNA Therapeutics 6/25/2012 10:56:20 AM
Sirnaomics Names China Partner for siRNA Therapeutic 6/23/2011 3:41:37 PM
Sirnaomics Seals a Second Partnership Deal with a Chinese Pharmaceutical Company for Developing siRNA Therapeutics 6/23/2011 9:34:56 AM
Sirnaomics Receives Two SBIR Grants from National Institutes of Health (NIH) for Developing siRNA Therapeutics to Treat Glioblastoma and Influenza Infection 6/29/2010 11:15:15 AM
12
//-->